Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s share price shot up 17.1% on Tuesday . The company traded as high as $5.20 and last traded at $5.13. 1,054,397 shares traded hands during mid-day trading, an increase of 78% from the average session volume of 591,401 shares. The stock had previously closed at $4.38.

CNAT has been the topic of several research analyst reports. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Seaport Global Securities reaffirmed a “buy” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.00.

The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The business had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same quarter last year, the company earned ($0.31) EPS. analysts forecast that Conatus Pharmaceuticals Inc will post -0.65 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNAT. Renaissance Technologies LLC raised its stake in Conatus Pharmaceuticals by 28.1% during the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock worth $1,358,000 after acquiring an additional 51,590 shares during the period. Bank of Montreal Can acquired a new stake in Conatus Pharmaceuticals during the second quarter worth about $109,000. Russell Investments Group Ltd. acquired a new stake in Conatus Pharmaceuticals during the second quarter worth about $679,000. Strs Ohio acquired a new stake in Conatus Pharmaceuticals during the second quarter worth about $153,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Conatus Pharmaceuticals during the second quarter worth about $1,041,000. Hedge funds and other institutional investors own 36.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/conatus-pharmaceuticals-cnat-shares-up-17-1/1776254.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.